MLYS · Healthcare
MINERALYS THERAPEUTICS INC
Smart-money confidence
· 1 of 3 sources firing
Bearish — money moving out
No standout activity across the feeds we track.
Hedge funds
32
Congress
No data
Insiders
No data
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
◆ Next steps
Interested in MINERALYS THERAPEUTICS INC? Here's what to do with it.
◇
Compare with other stocks
Sort 7,111 stocks by confidence, holders, or Congress signal
◈
Backtest the strategy
See how the model has done historically before you commit real money
✉
Get the weekly digest
One email on Sunday · what changed in the model this week
Not financial advice. Bogen Capital surfaces public SEC filings — you decide what to do with them.
Market cap
$2.4B
Industry
Biotechnology
Sector
Healthcare
Exchange
NasdaqGS
About MINERALYS THERAPEUTICS INC
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019…
Who's behind the signal
Every informed buyer we can see on MLYS, across all three feeds.
Hedge funds · 6
Tudor Investment (Paul Tudor Jones)
New position
D.E. Shaw & Co
Increased +88%
AQR Capital Management
Increased +244%
Point72 (Steve Cohen)
Decreased −33%
Citadel Advisors
Decreased −81%
Millennium Management (Englander)
Decreased −81%
Congress · 0
No congressional trades on record.
Insiders
No significant Form 4 insider activity in the window.
Not a model pick — but on our radar.
MINERALYS THERAPEUTICS INC isn't in the top-10 model right now, but 6 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
6
Investors
1
New positions
2
Increasing
3
Decreasing
0
Unchanged
Price History
Loading price data...
Return:
High:
Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.2×
% of portfolio
0.0%
Position change
NEW
0.0% of Tudor Investment's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+88%
0.0% of D.E. Shaw & Co's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+244%
0.0% of AQR Capital Management's portfolio
Trust weight: 1.1×
% of portfolio
0.1%
Position change
−33%
0.1% of Point72's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−81%
0.0% of Citadel Advisors's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−81%
0.0% of Millennium Management's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to MINERALYS THERAPEUTICS INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell MINERALYS THERAPEUTICS INC or any security.
Get the Weekly Update
Every Sunday, we'll send you what Buffett, Dalio, Ackman and 47 other legendary investors are buying — free, straight from their SEC filings.
Free forever · No spam · Unsubscribe anytime